MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - GLENMARK PHARMA
ASTRAZENECA PHARMA vs GLENMARK PHARMA - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
GLENMARK PHARMA 
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Current Valuations
| ASTRAZENECA PHARMA | GLENMARK PHARMA | ASTRAZENECA PHARMA/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 91.2 | 12.3 | 743.0% | View Chart |
| P/BV | x | 27.6 | 1.6 | 1,759.7% | View Chart |
| Dividend Yield | % | 0.0 | 0.6 | - |
Financials
 ASTRAZENECA PHARMA  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
GLENMARK PHARMA Mar-19 |
ASTRAZENECA PHARMA/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 712 | 179.6% | |
| Low | Rs | 883 | 484 | 182.5% | |
| Sales per share (Unadj.) | Rs | 228.4 | 349.6 | 65.3% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 32.8 | 31.6% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 44.3 | 36.7% | |
| Dividends per share (Unadj.) | Rs | 0 | 2.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.3 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 198.6 | 49.7% | |
| Shares outstanding (eoy) | m | 25.00 | 282.17 | 8.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 1.7 | 276.7% | |
| Avg P/E ratio | x | 104.2 | 18.2 | 571.8% | |
| P/CF ratio (eoy) | x | 66.4 | 13.5 | 492.9% | |
| Price / Book Value ratio | x | 10.9 | 3.0 | 363.6% | |
| Dividend payout | % | 0 | 6.1 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 168,625 | 16.0% | |
| No. of employees | `000 | 1.4 | 12.0 | 11.3% | |
| Total wages/salary | Rs m | 1,535 | 20,561 | 7.5% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 8,196.0 | 51.4% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 1,708.1 | 66.3% | |
| Avg. net profit/employee | Rs Th | 191.1 | 768.5 | 24.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 98,655 | 5.8% | |
| Other income | Rs m | 123 | 2,081 | 5.9% | |
| Total revenues | Rs m | 5,833 | 100,736 | 5.8% | |
| Gross profit | Rs m | 463 | 15,858 | 2.9% | |
| Depreciation | Rs m | 147 | 3,259 | 4.5% | |
| Interest | Rs m | 0 | 3,346 | 0.0% | |
| Profit before tax | Rs m | 438 | 11,335 | 3.9% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
| Tax | Rs m | 179 | 3,756 | 4.8% | |
| Profit after tax | Rs m | 259 | 9,250 | 2.8% | |
| Gross profit margin | % | 8.1 | 16.1 | 50.4% | |
| Effective tax rate | % | 40.8 | 33.1 | 123.2% | |
| Net profit margin | % | 4.5 | 9.4 | 48.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 66,968 | 4.8% | |
| Current liabilities | Rs m | 2,070 | 40,211 | 5.1% | |
| Net working cap to sales | % | 20.0 | 27.1 | 73.6% | |
| Current ratio | x | 1.6 | 1.7 | 93.1% | |
| Inventory Days | Days | 72 | 83 | 86.8% | |
| Debtors Days | Days | 35 | 81 | 43.0% | |
| Net fixed assets | Rs m | 790 | 33,322 | 2.4% | |
| Share capital | Rs m | 50 | 282 | 17.7% | |
| "Free" reserves | Rs m | 2,419 | 55,770 | 4.3% | |
| Net worth | Rs m | 2,469 | 56,052 | 4.4% | |
| Long term debt | Rs m | 0 | 35,738 | 0.0% | |
| Total assets | Rs m | 4,605 | 132,888 | 3.5% | |
| Interest coverage | x | NM | 4.4 | - | |
| Debt to equity ratio | x | 0 | 0.6 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.7 | 167.0% | |
| Return on assets | % | 5.6 | 9.5 | 59.4% | |
| Return on equity | % | 10.5 | 16.5 | 63.6% | |
| Return on capital | % | 17.7 | 17.8 | 99.6% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 62,998 | 0.5% | |
| Fx outflow | Rs m | 2,015 | 22,859 | 8.8% | |
| Net fx | Rs m | -1,715 | 40,140 | -4.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 13,242 | 0.7% | |
| From Investments | Rs m | -94 | -6,990 | 1.3% | |
| From Financial Activity | Rs m | NA | -7,387 | 0.0% | |
| Net Cashflow | Rs m | -6 | -2,971 | 0.2% | |
Share Holding
| Indian Promoters | % | 0.0 | 48.3 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 6.9 | 4.3% | |
| FIIs | % | 15.7 | 34.4 | 45.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 10.5 | 86.7% | |
| Shareholders | 12,856 | 56,727 | 22.7% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: CADILA HEALTHCARE J.B.CHEMICALS ORCHID PHARMA LTD BIOCON FULFORD INDIA
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 161 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)
Indian share markets witnessed selling pressure throughout the day and ended lower, tracking weakness in global markets owing to coronavirus outbreak.
Related Views on News
GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 5, 2019 | Updated on Sep 5, 2019Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)
Jun 3, 2019 | Updated on Jun 3, 2019For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)
Feb 5, 2020I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...
This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)
Feb 11, 2020A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.
Will Your Trade Go Up or Down Today?(Fast Profits Daily)
Feb 5, 2020How you can find out which way your trade is likely to move on any given trading day.
Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)
Feb 11, 2020How to fight back against algo trading systems.
No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)
Feb 6, 2020Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.
MoreOUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- 7 Stocks to Ride the Coming Rebirth of India Rally. Full Details Here...
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
ASTRAZENECA PHARMA SHARE PRICE
Feb 18, 2020 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 8-QTR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.